

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 6 SEP 27 STANDARDS will no longer be available on STN  
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN  
NEWS 8 OCT 28 KOREAPAT now available on STN  
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current  
search transcripts to be affected by CERAB, COMPUAB, ELCOM,  
and SOLIDSTATE reloads  
NEWS 10 NOV 30 PHAR reloaded with additional data  
NEWS 11 DEC 01 LISA now available on STN

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:10:16 ON 01 DEC 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:10:42 ON 01 DEC 2004

FILE 'USPATFULL' ENTERED AT 17:10:42 ON 01 DEC 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:10:42 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 17:10:42 ON 01 DEC 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:10:42 ON 01 DEC 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 17:10:42 ON 01 DEC 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 17:10:42 ON 01 DEC 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 17:10:42 ON 01 DEC 2004  
Copyright (c) 2004 The Thomson Corporation.

=> s carrier and bioresorbable

L1 524 CARRIER AND BIORESORBABLE

=> s l1 and biocompatible

L2 367 L1 AND BIOCOMPATIBLE

=> s BMP

L3 22208 BMP

=> s OP

L4 69969 OP

=> s l3 and l4

L5 2177 L3 AND L4

=> s l5 and l2

L6 38 L5 AND L2

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 38 USPATFULL on STN

TI In-situ formed intervertebral fusion device and method

AB An orthopedic device for implanting between adjacent vertebrae comprising: an arcuate balloon and a hardenable material within said balloon.

In some embodiments, the balloon has a footprint that substantially corresponds to a perimeter of a vertebral endplate. An inflatable device is inserted through a cannula into an intervertebral space and oriented so that, upon expansion, a natural angle between vertebrae will be at least partially restored. At least one component selected from the group consisting of a load-bearing component and an osteobiologic component is directed into the inflatable device through a fluid communication means.

ACCESSION NUMBER:

2004:293217 USPATFULL

TITLE:

In-situ formed intervertebral fusion device and method

INVENTOR(S):

DiMauro, Thomas M., Southboro, MA, UNITED STATES  
Slivka, Michael Andrew, Taunton, MA, UNITED STATES  
Malone, John Daniel, Cumberland, RI, UNITED STATES  
Moore, Bradley Thomas, Barrington, RI, UNITED STATES  
Serhan, Hassan, South Easton, MA, UNITED STATES  
Kadiyala, Sudhakar, South Easton, MA, UNITED STATES  
Bartish, Charles M., JR., Providence, RI, UNITED STATES  
Woodrow, Hal Brent, Princeton, NJ, UNITED STATES  
Rohr, William L., Palm Beach Gardens, FL, UNITED STATES  
Kelly, James Edward, North Easton, MA, UNITED STATES  
Cooper, Kevin, Flemington, NJ, UNITED STATES

PATENT ASSIGNEE(S): Aquino, Lauren, Boston, MA, UNITED STATES  
DePuy Spine, Inc., Raynham, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004230309	A1	20041118
APPLICATION INFO.:	US 2004-778684	A1	20040213 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-448221P	20030214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	104	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Page(s)	
LINE COUNT:	5024	

L6 ANSWER 2 OF 38 USPATFULL on STN  
TI Transdiscal administration of specific inhibitors of P38 kinase  
AB The present invention relates to injecting a high specificity p38 kinase inhibitor into a diseased intervertebral disc.

ACCESSION NUMBER: 2004:292789 USPATFULL  
TITLE: Transdiscal administration of specific inhibitors of P38 kinase  
INVENTOR(S): DiMauro, Thomas M., Southboro, MA, UNITED STATES  
Serhan, Hassan, South Easton, MA, UNITED STATES  
Attawia, Mohamed, Canton, MA, UNITED STATES  
Grace, Melissa, Raynham, MA, UNITED STATES  
Kadiyala, Sudhakar, South Easton, MA, UNITED STATES  
Urbahns, David, Barrington, RI, UNITED STATES  
Bruder, Scott, Sudbury, MA, UNITED STATES  
Collins, Gregory, East Sandwich, MA, UNITED STATES  
Brown, Laura J., Hamilton Square, NJ, UNITED STATES  
Geesin, Jeff, Doylestown, PA, UNITED STATES  
Plouhar, Pamela L., South Bend, IN, UNITED STATES  
Smith, Catherine, East Falmouth, MA, UNITED STATES  
Siekierka, John, Towaco, NJ, UNITED STATES  
PATENT ASSIGNEE(S): DePuy Spine, Inc., Raynham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229878	A1	20041118
APPLICATION INFO.:	US 2003-631487	A1	20030731 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-610355, filed on 30 Jun 2003, PENDING Continuation-in-part of Ser. No. US 2003-456948, filed on 6 Jun 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-470098P	20030513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	75	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1455	

L6 ANSWER 3 OF 38 USPATFULL on STN

TI Transdiscal administration of high affinity anti-MMP inhibitors  
AB The present invention relates to injecting a high affinity antagonist of  
MMPs into a diseased intervertebral disc.

ACCESSION NUMBER: 2004:291773 USPATFULL  
TITLE: Transdiscal administration of high affinity anti-MMP  
inhibitors  
INVENTOR(S): Serhan, Hassan, South Easton, MA, UNITED STATES  
DiMauro, Thomas M., Southboro, MA, UNITED STATES  
Attawia, Mohamed, Canton, MA, UNITED STATES  
Grace, Melissa, Raynham, MA, UNITED STATES  
Kadiyala, Sudhakar, South Easton, MA, UNITED STATES  
Urbahns, David, Barrington, RI, UNITED STATES  
Bruder, Scott, Sudbury, MA, UNITED STATES  
Collins, Gregory, East Sandwich, MA, UNITED STATES  
PATENT ASSIGNEE(S): DePuy Spine, Inc., Raynham, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004228853	A1	20041118
APPLICATION INFO.:	US 2003-610355	A1	20030630 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-456948, filed on 6 Jun 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-470098P	20030513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
LINE COUNT:	941	

L6 ANSWER 4 OF 38 USPATFULL on STN

TI Computer system and methods for producing morphogen analogs of human  
TDF-1  
AB The invention disclosed herein provides methods and compositions for the  
computer-assisted design of morphogen analogs. Practice of the invention  
is enabled by the use of at least a portion of the atomic co-ordinates  
defining the three-dimensional structure of human transformation and  
differentiation factor-1 (hTDF-1) as a starting point in the design of  
the morphogen analogs. In addition, the invention provides methods for  
producing morphogen analogs of interest, and methods for testing whether  
the resulting analogs mimic or agonize human TDF-1-like biological  
activity. The invention also provides a family of morphogen analogs  
produced by such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:121745 USPATFULL  
TITLE: Computer system and methods for producing morphogen  
analogues of human TDF-1  
INVENTOR(S): Carlson, William D., Weston, MA, UNITED STATES  
Keck, Peter C., Millbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004093164	A1	20040513
APPLICATION INFO.:	US 2002-290554	A1	20021108 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111		

NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 54 Drawing Page(s)  
LINE COUNT: 2926  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 38 USPATFULL on STN

TI Mutations of the C-terminal portion of TGF- $\beta$  superfamily proteins  
AB The invention provides modified proteins and DNAs of the TGF- $\beta$  superfamily including modified morphogenic proteins. The proteins of the present invention display altered biological or biochemical attributes. Specifically, the modified proteins are designed through substitutions of amino acids in the finger 2 sub-domain or exchanges of all or part of the finger 2 sub-domain of one TGF- $\beta$  superfamily member with the finger 2 sub-domain of another TGF- $\beta$  superfamily member.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:9647 USPATFULL  
TITLE: Mutations of the C-terminal portion of TGF- $\beta$  superfamily proteins  
INVENTOR(S): Oppermann, Hermann, Medway, MA, United States  
Tai, Mei-Sheng, Shrewsbury, MA, United States  
McCartney, John, Holliston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677432	B1	20040113
APPLICATION INFO.:	US 1999-374958		19990816 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-103418P	19981007 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Spector, Lorraine	
ASSISTANT EXAMINER:	Seharaseyon, Jegatheesan	
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, Jr., James F., Mangasarian, Karen	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	4992	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 38 USPATFULL on STN

TI Morphogen analogs of bone morphogenic proteins  
AB The present invention relates to morphogen analogs, particularly analogs of a **BMP**, such as **OP-1**, that are agonists or antagonists of a **BMP**, such as **OP-1**, biological activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:264778 USPATFULL  
TITLE: Morphogen analogs of bone morphogenic proteins  
INVENTOR(S): Keck, Peter C., Millbury, MA, UNITED STATES  
Bosukonda, Dattatreyamurty, Shrewsbury, MA, UNITED STATES  
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003185792	A1	20031002
APPLICATION INFO.:	US 2002-164279	A1	20020606 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-791946, filed on 22 Feb 2001, PENDING Continuation of Ser. No. US 1997-786284, filed on 22 Jan 1997, GRANTED, Pat. No. US 6273598 Continuation-in-part of Ser. No. US 1996-589552, filed on 22 Jan 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-354820P	20020205 (60)
	US 2002-371298P	20020410 (60)
	US 2001-296291P	20010606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Page(s)	
LINE COUNT:	4870	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 38 USPATFULL on STN  
TI Single chain analogs of the TGF-beta superfamily (morphons)  
AB Disclosed are a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF- $\beta$  superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complimentary to the ligand binding surface of a receptor that binds a TGF- $\beta$  superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF- $\beta$  superfamily.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:251878 USPATFULL  
TITLE: Single chain analogs of the TGF-beta superfamily (morphons)  
INVENTOR(S): Keck, Peter C., Millbury, MA, UNITED STATES  
Smart, John E., Weston, MA, UNITED STATES  
PATENT ASSIGNEE(S): Stryker Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176667	A1	20030918
APPLICATION INFO.:	US 2002-187394	A1	20020628 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-496398, filed on 2 Feb 2000, GRANTED, Pat. No. US 6479643 Continuation of Ser. No. US 1995-478097, filed on 7 Jun 1995, GRANTED, Pat. No. US 6040431		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET, BOSTON, MA, 02110		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Page(s)		
LINE COUNT:	4012		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 38 USPATFULL on STN  
TI Metal reinforced biodegradable intraluminal stents  
AB The present invention provides an intraluminal stent comprising a

metallic reinforcing component and a biodegradable polymeric material covering at least a portion of the metallic reinforcing component. The metallic reinforcing component provides structural reinforcement for the stent, but this reinforcement is insufficient, in the absence of the biodegradable polymeric material, to provide a stent capable of maintaining patency of a lumen upon implantation of the stent into the lumen. One advantage of the present invention, among others, is that a stent is provided in which reduced amounts of metallic component remain after degradation of the biodegradable polymeric material covering, in turn reducing the incidence of metal-associated adverse events that frequently follow implantation.

ACCESSION NUMBER: 2003:220679 USPATFULL  
 TITLE: Metal reinforced biodegradable intraluminal stents  
 INVENTOR(S): Chandrasekaran, Chandru, Mercer Island, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153971	A1	20030814
APPLICATION INFO.:	US 2002-75914	A1	20020214 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MAYER, FORTKORT & WILLIAMS, PC, 251 NORTH AVENUE WEST, 2ND FLOOR, WESTFIELD, NJ, 07090		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	951		

L6 ANSWER 9 OF 38 USPATFULL on STN  
 TI Methods and compositions for the treatment and prevention of parkinson's disease  
 AB Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:159830 USPATFULL  
 TITLE: Methods and compositions for the treatment and prevention of parkinson's disease  
 INVENTOR(S): Rueger, David C., Southborough, MA, UNITED STATES  
 Sampath, Kuber T., Holliston, MA, UNITED STATES  
 Cohen, Charles M., Weston, MA, UNITED STATES  
 Oppermann, Hermann, Medway, MA, UNITED STATES  
 Pang, Roy H.L., Etna, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109445	A1	20030612
APPLICATION INFO.:	US 2002-272503	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-938622, filed on 25 Sep 1997, GRANTED, Pat. No. US 6506729		
	Continuation-in-part of Ser. No. US 1994-260675, filed on 16 Jun 1994, PENDING Continuation of Ser. No. US 1993-126100, filed on 23 Sep 1993, ABANDONED		

Continuation of Ser. No. US 1992-922813, filed on 31 Jul 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, ABANDONED

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 13 Drawing Page(s)  
LINE COUNT: 3035  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 38 USPATFULL on STN

TI Shaped particle comprised of bone material and method of making the particle

AB A shaped particle for use in an array of interlocking particles to repair, replace, improve or augment a bone deficiency is provided. The particle is comprised of bone material and, in a preferred embodiment, has six extremities, and the interstitial spaces between the extremities of one particle accept the extremities of an adjacent particle in an array. In a preferred embodiment, the bone material is demineralized bone material. In some embodiments, the particle is suspended in a material that facilitates application of the particle to bone, and the material may contain biological factors that augment bone growth or prevent infection.

ACCESSION NUMBER: 2003:79582 USPATFULL  
TITLE: Shaped particle comprised of bone material and method of making the particle  
INVENTOR(S): Schryver, Jeffrey E., Cordova, TN, UNITED STATES  
Cooper, Michael B., Memphis, TN, UNITED STATES  
Kinnane, Keith M., Bartlett, TN, UNITED STATES  
Long, Marc, Memphis, TN, UNITED STATES  
Allen, Trevor, York, UNITED KINGDOM  
Margerrison, Ed, York, UNITED KINGDOM  
Morgan, Robert, UNITED STATES  
Bearcroft, Julie A., Bartlett, TN, UNITED STATES  
Harrison, Andrew, York, UNITED KINGDOM  
Kaiser, William B., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055511	A1	20030320
APPLICATION INFO.:	US 2002-99616	A1	20020315 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-517981, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2001-792681, filed on 23 Feb 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Smith & Nephew, Inc., 1450 Brooks Road, Memphis, TN, 38116		
NUMBER OF CLAIMS:	103		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	36 Drawing Page(s)		
LINE COUNT:	3099		

L6 ANSWER 11 OF 38 USPATFULL on STN

TI Cartilage repair and regeneration device and method

AB A method for the repair of a cartilagenous tissue defect, a cartilage repair device and a method of making a cartilage repair device are



disclosed. In the method for the repair of a cartilagenous tissue defect, a device comprising a scaffold, for example an extracellular matrix material, is implanted into the defect, and a biological lubricant is administered to the defect. The device comprises a scaffold, for example a naturally occurring extracellular matrix material, and a biological lubricant.

ACCESSION NUMBER: 2003:45709 USPATFULL  
TITLE: Cartilage repair and regeneration device and method  
INVENTOR(S): Plouhar, Pamela Lynn, South Bend, IN, UNITED STATES  
Malaviya, Prasanna, Ft. Wayne, IN, UNITED STATES  
Schwartz, Herbert Eugene, Ft. Wayne, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003033022	A1	20030213
APPLICATION INFO.:	US 2002-195606	A1	20020715 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-388724P	20020614 (60)
	US 2001-305786P	20010716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BARNES & THORNBURG, 11 SOUTH MERIDIAN, INDIANAPOLIS, IN, 46204	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1074	

L6 ANSWER 12 OF 38 USPATFULL on STN  
TI Methods for enhancing functional recovery following central nervous system ischemia or trauma  
AB The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF- $\beta$  superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:30881 USPATFULL  
TITLE: Methods for enhancing functional recovery following central nervous system ischemia or trauma  
INVENTOR(S): Charette, Marc F., Needham, MA, UNITED STATES  
Finklestein, Seth P., Needham, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022830	A1	20030130
APPLICATION INFO.:	US 2002-62370	A1	20020201 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-828281, filed on 21 Mar 1997, PENDING Continuation-in-part of Ser. No. US 1996-620444, filed on 22 Mar 1996, ABANDONED		
DOCUMENT TYPE:	Utility		

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,  
02110-2624  
NUMBER OF CLAIMS: 26  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Page(s)  
LINE COUNT: 2127  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 38 USPATFULL on STN  
TI Methods and compositions for the treatment and prevention of Parkinson's  
disease  
AB Disclosed are therapeutic treatment methods, compositions and devices  
for maintaining neural pathways in a mammal, including enhancing  
survival of neurons at risk of dying, inducing cellular repair of  
damaged neurons and neural pathways, and stimulating neurons to maintain  
their differentiated phenotype. In one embodiment, the invention  
provides means for stimulating CAM expression in neurons. The invention  
also provides means for evaluating the status of nerve tissue, including  
means for detecting and monitoring neuropathies in a mammal. The  
methods, devices and compositions include a morphogen or  
morphogen-stimulating agent provided to the mammal in a therapeutically  
effective concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:13291 USPATFULL  
TITLE: Methods and compositions for the treatment and  
prevention of Parkinson's disease  
INVENTOR(S): Rueger, David C., Southborough, MA, United States  
Sampath, Kuber T., Holliston, MA, United States  
Cohen, Charles M., Weston, MA, United States  
Oppermann, Hermann, Medway, MA, United States  
Pang, Roy H. L., Etna, NH, United States  
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6506729	B1	20030114
APPLICATION INFO.:	US 1997-938622		19970925 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-260675, filed on 16 Jun 1994 Continuation of Ser. No. US 1993-126100, filed on 23 Sep 1993, now abandoned Continuation of Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 8 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Ropes & Gray		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2995		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 38 USPATFULL on STN  
TI Morphogen treatment for chronic renal failure  
AB The present invention provides methods for the treatment, and

pharmaceuticals for use in the treatment, of mammalian subjects at risk chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain morphogens, inducers of those morphogens, or agonists of the corresponding morphogen receptors, or implantation of renal cells induced with those morphogens. The morphogens useful in the invention include osteogenic protein-1 (OP-1) and other members of the OP-1 subfamily of the TGF- $\beta$  superfamily of growth factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:340311 USPATFULL  
TITLE: Morphogen treatment for chronic renal failure  
INVENTOR(S): Sampath, Kuber T., Holliston, MA, United States  
Cohen, Charles M., Weston, MA, United States  
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6498142	B1	20021224
APPLICATION INFO.:	US 1996-643321		19960506 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Celsa, Bennett		
LEGAL REPRESENTATIVE:	Ropes & Gray, Vincent, Matthew P., Schneider, Spencer		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	3342		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 38 USPATFULL on STN

TI Single chain analogs of the TGF- $\beta$  superfamily (morphons)  
AB Disclosed are a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF- $\beta$  superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complimentary to the ligand binding surface of a receptor that binds a TGF- $\beta$  superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF- $\beta$  superfamily.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:297691 USPATFULL  
TITLE: Single chain analogs of the TGF- $\beta$  superfamily (morphons)  
INVENTOR(S): Keck, Peter C., Millbury, MA, United States  
Smart, John E., Weston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479643	B1	20021112
APPLICATION INFO.:	US 2000-496398		20000202 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-478097, filed on 7 Jun 1995, now patented, Pat. No. US 6040431, issued on 21 Sep 2000		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Allen, Marianne P.		

LEGAL REPRESENTATIVE: Testa, Hurwitz & Thibault, LLP  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 23 Drawing Page(s)  
LINE COUNT: 3930  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 38 USPATFULL on STN

TI Terminally sterilized osteogenic devices and preparation thereof  
AB Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble **carrier** which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

ACCESSION NUMBER: 2002:262069 USPATFULL  
TITLE: Terminally sterilized osteogenic devices and preparation thereof  
INVENTOR(S): Tucker, Marjorie M., Holliston, MA, United States  
Rueger, David C., Southborough, MA, United States  
Sampath, Kuber T., Holliston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6461630	B1	20021008
APPLICATION INFO.:	US 1999-450541		19991130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-159535, filed on 23 Sep 1998, now patented, Pat. No. US 6013856		
	Continuation of Ser. No. US 1997-881307, filed on 24 Jun 1997, now patented, Pat. No. US 6028242 Division of Ser. No. US 1995-478452, filed on 7 Jun 1995, now patented, Pat. No. US 5674292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Fredman, Jeffrey		
ASSISTANT EXAMINER:	Chakrabarti, Arun K.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibault, LLP		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1439		

L6 ANSWER 17 OF 38 USPATFULL on STN

TI Terminally sterilized osteogenic devices and preparation thereof  
AB Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble **carrier** which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

ACCESSION NUMBER: 2002:198300 USPATFULL  
TITLE: Terminally sterilized osteogenic devices and  
preparation thereof  
INVENTOR(S): Tucker, Marjorie M., Holliston, MA, UNITED STATES  
Rueger, David C., Southborough, MA, UNITED STATES  
Sampath, Kuber T., Holliston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106394	A1	20020808
	US 6504079	B2	20030107
APPLICATION INFO.:	US 2001-954748	A1	20010918 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-450541, filed on 30 Nov 1999, PENDING Continuation of Ser. No. US 1998-159535, filed on 23 Sep 1998, GRANTED, Pat. No. US 6013856 Continuation of Ser. No. US 1997-881307, filed on 24 Jun 1997, GRANTED, Pat. No. US 6028242 Division of Ser. No. US 1995-478452, filed on 7 Jun 1995, GRANTED, Pat. No. US 5674292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET, BOSTON, MA, 02110		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1342		

L6 ANSWER 18 OF 38 USPATFULL on STN

TI Method for enhancing functional recovery following central nervous  
system ischemia or trauma

AB The present invention provides methods and compositions for treatment of  
mammals afflicted with an ischemic or traumatic injury of the central  
nervous system. The present invention capitalizes in part upon the  
discovery that administration of a morphogen to such a mammal provides  
significant improvement in central nervous system function, even when  
administered after central nervous system tissue has been damaged. The  
methods involve the administration of dimeric proteins defined as  
morphogens, inducers of these morphogens, or agonists of the  
corresponding morphogen receptors, or implantation of cells stimulated  
by exposure to the morphogens. The proteins defined as morphogens  
comprise a structurally and functionally distinct family within the  
TGF- $\beta$  superfamily. Osteogenic protein-1 (OP-1) is  
considered to be an exemplary and preferred member of this morphogen  
family.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:144236 USPATFULL  
TITLE: Method for enhancing functional recovery following  
central nervous system ischemia or trauma  
INVENTOR(S): Charette, Marc F., Needham, MA, United States  
Finklestein, Seth P., Needham, MA, United States  
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6407060	B1	20020618
APPLICATION INFO.:	US 1997-828281		19970321 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-620444, filed on 22 Mar 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Henley, III, Raymond		

ASSISTANT EXAMINER: Delacroix-Muirheid, C.  
LEGAL REPRESENTATIVE: Ropes & Gray  
NUMBER OF CLAIMS: 30  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)  
LINE COUNT: 2459  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 38 USPATFULL on STN  
TI Soluble morphogenic protein complex compositions of matter  
AB Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:122758 USPATFULL  
TITLE: Soluble morphogenic protein complex compositions of matter  
INVENTOR(S): Jones, William K., Brookline, MA, United States  
Tucker, Ronald F., Holliston, MA, United States  
Rueger, David C., Hopkinton, MA, United States  
Oppermann, Hermann, Medway, MA, United States  
Ozkaynak, Engin, Milford, MA, United States  
Kuberasampath, Thangavel, Medway, MA, United States  
PATENT ASSIGNEE(S): Curis, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395883	B1	20020528
APPLICATION INFO.:	US 1995-402542		19950313 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-40510, filed on 31 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1993-29335, filed on 4 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned Continuation-in-part of Ser. No. US 1992-946235, filed on 16 Sep 1992, now abandoned Continuation-in-part of Ser. No. US 1992-938336, filed on 28 Aug 1992, now abandoned Continuation-in-part of Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
LEGAL REPRESENTATIVE:	Testa Hurwitz & Thibeault		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1552		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 38 USPATFULL on STN  
TI METHODS AND COMPOSITIONS FOR THE TREATMENT OF MOTOR NEURON INJURY AND NEUROPATHY  
AB Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain

their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:92635 USPATFULL  
TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT OF MOTOR NEURON INJURY AND NEUROPATHY  
INVENTOR(S): RUEGER, DAVID C., SOUTHBOROUGH, MA, UNITED STATES  
SAMPATH, KUBER T., HOLLISTON, MA, UNITED STATES  
OPPERMANN, HERMAN, MEDWAY, MA, UNITED STATES  
PANG, ROY H. L., NEW HAMPSHIRE, MA, UNITED STATES  
COHEN, CHARLES M., WESTON, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049159	A1	20020425
	US 6723698	B2	20040420
APPLICATION INFO.:	US 1997-937755	A1	19970925 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-260675, filed on 16 Jun 1994, PENDING Continuation of Ser. No. US 1993-126100, filed on 23 Sep 1993, ABANDONED Continuation of Ser. No. US 1992-922813, filed on 31 Jul 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	IVOR R ELRIFI, MINTZ LEVIN, ONE FINANCIAL CENTER, BOSTON, MA, 02111		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	3688		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 38 USPATFULL on STN

TI Methods and compositions for producing morphogen analogs  
AB The invention disclosed herein provides methods and compositions for the computer-assisted design of morphogen analogs. Practice of the invention is enabled by the use of at least a portion of the atomic co-ordinates defining the three-dimensional structure of human osteogenic protein-1 (hOP-1) as a starting point in the design of the morphogen analogs. In addition, the invention provides methods for producing morphogen analogs of interest, and methods for testing whether the resulting analogs mimic or agonize human OP-1-like biological activity. The invention also provides a family of morphogen analogs produced by such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:48262 USPATFULL  
TITLE: Methods and compositions for producing morphogen analogs  
INVENTOR(S): Keck, Peter C., Millbury, MA, UNITED STATES  
Griffith, Diana L., Weston, MA, UNITED STATES  
Carlson, William D., Weston, MA, UNITED STATES  
Rueger, David C., Hopkinton, MA, UNITED STATES  
Sampath, Kuber T., Medway, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028453	A1	20020307
APPLICATION INFO.:	US 2001-791946	A1	20010222 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-786284, filed on 22 Jan 1997, GRANTED, Pat. No. US 6273598 Continuation-in-part of Ser. No. US 1996-589552, filed on 22 Jan 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	c/o MINTZ, LEVIN, One Financial Center, Boston, MA, 02111		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	98 Drawing Page(s)		
LINE COUNT:	2974		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 22 OF 38 USPATFULL on STN

TI Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases

AB The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:235237 USPATFULL

TITLE: Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases

INVENTOR(S): Kuberasampath, Thangavel, Medway, MA, United States  
Cohen, Charles M., Weston, MA, United States  
Oppermann, Herrmann, Medway, MA, United States  
Ozkaynak, Engin, Milford, MA, United States  
Rueger, David C., Hopkinton, MA, United States  
Smart, John E., Weston, MA, United States  
Pang, Roy H. L., Etna, NH, United States

PATENT ASSIGNEE(S): Curis, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333312	B1	20011225
APPLICATION INFO.:	US 1998-170936		19981013 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-432883, filed on 2 May 1995, now abandoned Continuation of Ser. No. US 1993-115914, filed on 1 Sep 1993, now abandoned Continuation of Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
LEGAL REPRESENTATIVE:	Walker, Shelby J., Morency, MichaelMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2203		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			



L6 ANSWER 23 OF 38 USPATFULL on STN

TI Repair of larynx, trachea, and other fibrocartilaginous tissues

AB Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:165613 USPATFULL

TITLE: Repair of larynx, trachea, and other fibrocartilaginous tissues

INVENTOR(S): Vukicevic, Slobodan, Zagreb, Croatia

Katic, Vladimir, Zagreb, Croatia

Sampath, Kuber T., Holliston, MA, United States

PATENT ASSIGNEE(S): Creative BioMolecules, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION:	US 2001024823	A1	20010927
---------------------	---------------	----	----------

APPLICATION INFO.:	US 2001-828607	A1	20010406 (9)
--------------------	----------------	----	--------------

RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US17222, filed on 30 Jul 1999, UNKNOWN		
-----------------------	---	--	--

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION:	US 1998-103161P	19981006 (60)
-----------------------	-----------------	---------------

DOCUMENT TYPE:	Utility	
----------------	---------	--

FILE SEGMENT:	APPLICATION	
---------------	-------------	--

LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
-----------------------	---	--

NUMBER OF CLAIMS:	56	
-------------------	----	--

EXEMPLARY CLAIM:	1	
------------------	---	--

LINE COUNT:	1859	
-------------	------	--

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 38 USPATFULL on STN

TI Computer system and methods for producing morphogen analogs of human OP-1

AB The invention disclosed herein provides methods and compositions for the computer-assisted design of morphogen analogs. Practice of the invention is enabled by the use of at least a portion of the atomic co-ordinates defining the three-dimensional structure of human osteogenic protein-1 (hOP-1) as a starting point in the design of the morphogen analogs. In addition, the invention provides methods for producing morphogen analogs of interest, and methods for testing whether the resulting analogs mimic or agonize human OP-1-like biological activity. The invention also provides a family of morphogen analogs produced by such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:130327 USPATFULL

TITLE: Computer system and methods for producing morphogen analogs of human OP-1

INVENTOR(S): Keck, Peter C., Millbury, MA, United States

Griffith, Diana L., Weston, MA, United States

Carlson, William D., Weston, MA, United States

Rueger, David C., Hopkinton, MA, United States

Sampath, Kuber T., Medway, MA, United States

PATENT ASSIGNEE(S): Creative BioMolecules, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 6273598 B1 20010814  
 APPLICATION INFO.: US 1997-786284 19970122 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-589552, filed  
 on 22 Jan 1996, now abandoned  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Horlick, Kenneth R.  
 ASSISTANT EXAMINER: Siew, Jeffrey  
 LEGAL REPRESENTATIVE: Elrifi, Ivor R., Morency, MichelMintz, Levin, Cohn,  
 Ferris, Glovsky & Popeo, PC  
 NUMBER OF CLAIMS: 21  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 108 Drawing Figure(s); 98 Drawing Page(s)  
 LINE COUNT: 2947  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 38 USPATFULL on STN  
 TI 60A protein-induced morphogenesis  
 AB Disclosed are methods of utilizing a morphogenically active fragment of  
 60A protein to induce tissue morphogenesis, including methods for  
 increasing a progenitor cell population in a mammal, methods for  
 stimulating progenitor cells to differentiate and maintain their  
 differentiated phenotype in vivo or in vitro, methods for inducing  
 tissue-specific growth in vivo and methods for the replacement of  
 diseased or damaged tissue in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:48020 USPATFULL  
 TITLE: 60A protein-induced morphogenesis  
 INVENTOR(S): Kuberasampath, Thangavel, Medway, MA, United States  
 Pang, Roy H. L., Etna, NH, United States  
 Oppermann, Hermann, Medway, MA, United States  
 Rueger, David C., Hopkinton, MA, United States  
 Cohen, Charles M., Medway, MA, United States  
 PATENT ASSIGNEE(S): Curis, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211146	B1	20010403
APPLICATION INFO.:	US 1994-271556		19940707 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-945292, filed on 15 Sep 1992, now abandoned Continuation-in-part of Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned Continuation-in-part of Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned Continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
LEGAL REPRESENTATIVE:	Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., Elrifi, Ivor R., Morency, Michel		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		

LINE COUNT: 2294  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 38 USPATFULL on STN  
TI Chitin hydrogels, methods of their production and use  
AB This invention is directed to the preparation and utilization of supplemented chitin hydrogels, such as chitosan hydrogels. Further provided are biomaterials comprising same. The particular supplement delivered by the chitin hydrogel is selected as a function of its intended use. In one embodiment, this invention provides a composition of matter, comprising a chitin hydrogel or chitin-derived hydrogel, wherein the hydrogel does not inhibit full-thickness skin wound healing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:128306 USPATFULL  
TITLE: Chitin hydrogels, methods of their production and use  
INVENTOR(S): Drohan, William N., Springfield, VA, United States  
MacPhee, Martin J., Gaithersburg, MD, United States  
Miekka, Shirley I., Gaithersburg, MD, United States  
Singh, Manish S., Columbia, MD, United States  
Elson, Clive, Halifax, Canada  
Taylor, Jr., John R., New York, NY, United States  
PATENT ASSIGNEE(S): Chitogenics, Inc., Morristown, NJ, United States (U.S. corporation)  
The American National Red Cross, Washington, DC, United States (U.S. corporation)  
Coalition for Hemophilia B, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6124273		20000926
APPLICATION INFO.:	US 1997-960555		19971013 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-659999, filed on 7 Jun 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-109P	19950609 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fonda, Kathleen K.	
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	2441	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 38 USPATFULL on STN  
TI Single chain analogs of the TGF- $\beta$  superfamily (morphons)  
AB Disclosed are a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF- $\beta$  superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biologically active subunit interacting finger and heel regions which together define a tertiary protein structure complimentary to the ligand binding surface of a receptor that binds a TGF- $\beta$  superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetermined receptors of the TGF- $\beta$  superfamily.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:34675 USPATFULL  
TITLE: Single chain analogs of the TGF- $\beta$  superfamily  
(morphons)  
INVENTOR(S): Keck, Peter C., Millbury, MA, United States  
Smart, John E., Weston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040431		20000321
APPLICATION INFO.:	US 1995-478097		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Allen, Marianne P.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault, LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	39 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	3912		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 38 USPATFULL on STN

TI Terminally sterilized osteogenic devices and preparation thereof  
AB Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble **carrier** which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

ACCESSION NUMBER: 2000:21736 USPATFULL  
TITLE: Terminally sterilized osteogenic devices and preparation thereof  
INVENTOR(S): Tucker, Marjorie M., Holliston, MA, United States  
Rueger, David C., Southborough, MA, United States  
Sampath, Kuber T., Holliston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6028242		20000222
APPLICATION INFO.:	US 1997-881307		19970624 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-478452, filed on 7 Jun 1995, now patented, Pat. No. US 5674292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Isabella, David J.		
ASSISTANT EXAMINER:	Black, John M.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault, LLP		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1416		

L6 ANSWER 29 OF 38 USPATFULL on STN

TI Terminally sterilized osteogenic devices and preparation thereof  
AB Disclosed are terminally sterilized osteogenic devices for implantation

into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble **carrier** which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

ACCESSION NUMBER: 2000:5017 USPATFULL  
 TITLE: Terminally sterilized osteogenic devices and preparation thereof  
 INVENTOR(S): Tucker, Marjorie M., Holliston, MA, United States  
 Rueger, David C., Southborough, MA, United States  
 Sampath, Kuber T., Holliston, MA, United States  
 PATENT ASSIGNEE(S): Stryker Corporation, Hopkinton, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013856		20000111
APPLICATION INFO.:	US 1998-159535		19980923 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-881307, filed on 24 Jun 1997 which is a division of Ser. No. US 1995-478452, filed on 7 Jun 1995, now patented, Pat. No. US 5674292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Smith, Jeffrey A.		
ASSISTANT EXAMINER:	Robert, Eduardo C.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault LLP		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1444		

L6 ANSWER 30 OF 38 USPATFULL on STN

TI Methods and compositions for multiple gene transfer into bone cells  
 AB Disclosed are methods, compositions, kits and devices for use in transferring nucleic acids into bone cells in situ and/or for stimulating bone progenitor cells. Type II collagen and, particularly, osteotropic genes, are shown to stimulate bone progenitor cells and to promote bone growth, repair and regeneration in vivo. Gene transfer protocols are disclosed for use in transferring various nucleic acid materials into bone, as may be used in treating various bone-related diseases and defects including fractures, osteoporosis, osteogenesis imperfecta and in connection with bone implants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:99644 USPATFULL  
 TITLE: Methods and compositions for multiple gene transfer into bone cells  
 INVENTOR(S): Bonadio, Jeffrey, Ann Harbor, MI, United States  
 Goldstein, Steven A., Ann Harbor, MI, United States  
 PATENT ASSIGNEE(S): The Regent of The University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5942496		19990824
APPLICATION INFO.:	US 1994-316650		19940930 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-199780, filed		

on 18 Feb 1994, now patented, Pat. No. US 5763416  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Campbell, Bruce R.  
ASSISTANT EXAMINER: Nguyen, Dave Trong  
LEGAL REPRESENTATIVE: Arnold White & Durkee  
NUMBER OF CLAIMS: 130  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 14 Drawing Page(s)  
LINE COUNT: 5310  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 38 USPATFULL on STN  
TI Morphogen-responsive signal transducer and methods of use thereof  
AB A novel gene, DD-10, and its encoded polypeptide chain, DD-10, expressed during early onset of morphogen-induced mammalian tissue morphogenesis, now has been discovered. Accordingly, the invention identifies a new gene which is a novel biological marker of cell differentiation and tissue morphogenesis, particularly of chondroblast or osteoblast cell differentiation and bone tissue morphogenesis. Disclosed are: (a) methods and compositions for screening for and producing morphogen analogs; (b) novel morphogen analogs; (c) downstream inducers of morphogenesis; (d) a novel marker for evaluating morphogen or morphogen analog dosing; and (e) therapeutic methods and compositions using these analogs and/or downstream inducers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:85291 USPATFULL  
TITLE: Morphogen-responsive signal transducer and methods of use thereof  
INVENTOR(S): Sampath, Kuber T., Holliston, MA, United States  
Takeda, Kohsuke, Ichikawa, Japan  
Ichijo, Hidenori, Tokyo, Japan  
PATENT ASSIGNEE(S): Creative BioMolecules, Inc., Boston, MA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5928940		19990727
APPLICATION INFO.:	US 1996-727118		19961008 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25311P	19960924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Campbell, Bruce R.	
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault, LLP	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	2733	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 38 USPATFULL on STN  
TI Matrix for the manufacture of autogenous replacement body parts  
AB Disclosed are matrices, devices and methods for the manufacture of live autogenous skeletal replacement parts comprising plural different tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:61014 USPATFULL  
TITLE: Matrix for the manufacture of autogenous replacement body parts

INVENTOR(S): Khouri, Roger K., St. Louis, MO, United States  
Sampath, Kuber T., Medway, MA, United States  
Rueger, David C., Hopkinton, MA, United States  
PATENT ASSIGNEE(S): Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5906827		19990525
APPLICATION INFO.:	US 1994-253398		19940603 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Mullis, Jeffrey C.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault, LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	383		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 38 USPATFULL on STN  
TI Terminally sterilized osteogenic devices and preparation thereof  
AB Disclosed are terminally sterilized osteogenic devices for implantation into a mammal. The devices contain a combination of a biologically active osteogenic protein and an insoluble **carrier** which after being combined are sterilized by exposure to ionizing radiation, for example, by exposure to gamma rays or an electron beam. The terminally sterilized devices of the invention are characterized in that they induce bone formation following implantation into a mammal. Also disclosed is a method for inducing bone formation in a mammal by implanting a terminally sterilized device of the invention into a preselected locus in a mammal. Also disclosed is a method for preparing the terminally sterilized device of the invention.

ACCESSION NUMBER: 97:90970 USPATFULL  
TITLE: Terminally sterilized osteogenic devices and preparation thereof  
INVENTOR(S): Tucker, Marjorie M., Holliston, MA, United States  
Rueger, David C., Southborough, MA, United States  
Sampath, Kuber T., Holliston, MA, United States  
PATENT ASSIGNEE(S): Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674292		19971007
APPLICATION INFO.:	US 1995-478452		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
LEGAL REPRESENTATIVE:	Testa, Hurwitz & Thibeault, LLP		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1423		

L6 ANSWER 34 OF 38 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
TI Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**  
AN AAY92441 protein DGENE  
AB Generic Sequence 10 contains generic sequence 9 and an N-terminal extension. Generic sequence 9 is a composite amino acid sequence of the following proteins: human OP-1 to -3, human BMP-2 to

Appd

-6, -9 to -11, Drosophila 60A, Xenopus Vg-1, sea urchin UNIVIN, human CDMP-1 to -3, human and mouse GDF-1, chicken DORSALIN, DPP, Drosophila Screw, mouse NODAL, mouse GDF-8 to -11, human GDF-8, -11, human **BMP-15** and rat BMP3b. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92441 protein DGENE

TITLE: Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T

PATENT ASSIGNEE: (STYC)STRYKER CORP.

PATENT INFO: WO 2000020021 A1 20000413 65p

APPLICATION INFO: WO 1999-US17222 19990730

PRIORITY INFO: US 1998-103161 19981006

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-317644 [27]

DESCRIPTION: Generic sequence 10, derived from osteogenic protein family members.

L6 ANSWER 35 OF 38 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

AN AAY92440 protein DGENE

AB Generic Sequence 9 is a composite amino acid sequence of the following proteins: human **OP-1** to -3, human **BMP-2** to -6, -9 to -11, Drosophila 60A, Xenopus Vg-1, sea urchin UNIVIN, human CDMP-1 to -3, human and mouse GDF-1, chicken DORSALIN, DPP, Drosophila Screw, mouse NODAL, mouse GDF-8 to -11, human GDF-8, -11, human **BMP-15** and rat BMP3b. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92440 protein DGENE

TITLE: Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T

PATENT ASSIGNEE: (STYC)STRYKER CORP.

PATENT INFO: WO 2000020021 A1 20000413 65p

APPLICATION INFO: WO 1999-US17222 19990730

PRIORITY INFO: US 1998-103161 19981006

DOCUMENT TYPE: Patent



LANGUAGE: English  
OTHER SOURCE: 2000-317644 [27]  
DESCRIPTION: Generic sequence 9, derived from osteogenic protein family members.

L6 ANSWER 36 OF 38 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
TI Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

AN AAY92439 protein DGENE  
AB Generic Sequence 8 contains generic sequence 7 (AAY92438), which accomodates the homologies shared among osteogenic protein family members, including OP-1, OP-2, OP-3, BMP-2 to -6, 60A, DPP, Vg-1, Vgr-1 and GDF, as well as an N-terminal addition of 5 residues. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92439 protein DGENE  
TITLE: Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T  
PATENT ASSIGNEE: (STYC)STRYKER CORP.  
PATENT INFO: WO 2000020021 A1 20000413 65p  
APPLICATION INFO: WO 1999-US17222 19990730  
PRIORITY INFO: US 1998-103161 19981006  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-317644 [27]  
DESCRIPTION: Generic sequence 8, derived from osteogenic protein family members.

L6 ANSWER 37 OF 38 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
TI Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

AN AAY92438 protein DGENE  
AB Generic Sequence 7 accomodates the homologies shared among osteogenic protein family members, including OP-1, OP-2, OP-3, BMP-2 to -6, 60A, DPP, Vg-1, Vgr-1 and GDF. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92438 protein DGENE

TITLE: Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T

PATENT ASSIGNEE: (STYC)STRYKER CORP.

PATENT INFO: WO 2000020021 A1 20000413 65p

APPLICATION INFO: WO 1999-US17222 19990730

PRIORITY INFO: US 1998-103161 19981006

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-317644 [27]

DESCRIPTION: Generic sequence 7, derived from osteogenic protein family members.

L6 ANSWER 38 OF 38 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

TI Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**.

AN 2000-317644 [27] WPIDS

CR 2000-317706 [27]

AB WO 200020021 A UPAB: 20041026

NOVELTY - Repairing a defect in a nonarticular cartilage tissue or a ligament of a mammal, comprising providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus, inducing the formation of functional replacement cartilage, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an implantable device for repairing a defect in a nonarticular cartilage tissue comprising an osteogenic protein disposed in a devitalized cartilage, a collagen **carrier**, or a carboxymethylcellulose **carrier**; and

(2) promoting chondrogenesis at a defect locus in a mammal comprising providing an osteogenic protein in a devitalized cartilage **carrier** that is configured to fit into the defect locus.

ACTIVITY - Osteogenic; chondrogenic.

MECHANISM OF ACTION - Osteopathic stimulating implant; transplantation.

USE - The methods and implants are useful for repairing or correcting a defect in a nonarticular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, edema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, vertebral discs, and interarticular menisci.

Dwg.0/0

ACCESSION NUMBER: 2000-317644 [27] WPIDS

CROSS REFERENCE: 2000-317706 [27]

DOC. NO. CPI: C2000-096081

TITLE: Novel methods for repairing a defect in mammalian nonarticular cartilage tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**.

DERWENT CLASS: A96 B04 D22

INVENTOR(S): AN, H; MASUDA, K; THONAR, E J A; KATIC, V; SAMPATH, K T; VUKICEVIC, S

PATENT ASSIGNEE(S): (ANHH-I) AN H; (RUSH-N) RUSH PRESBYTERIAN ST LUKE MEDICAL CENT; (STYC) STRYKER CORP; (CREA-N) CREATIVE BIOMOLECULES INC

COUNTRY COUNT: 23

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

```

-----
WO 2000020021  A1 20000413 (200027)* EN 64
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP US
AU 9952417      A 20000426 (200036)
EP 1117422      A1 20010725 (200143) EN
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 2001024823   A1 20010927 (200159)
JP 2002526167   W 20020820 (200258) 70
AU 772479       B2 20040429 (200457)
AU 2004202345   A1 20040624 (200468)#

```

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000020021	A1	WO 1999-US17222	19990730
AU 9952417	A	AU 1999-52417	19990730
EP 1117422	A1	EP 1999-937624	19990730
		WO 1999-US17222	19990730
US 2001024823	A1 Provisional	US 1998-103161P	19981006
	Cont of	WO 1999-US17222	19990730
		US 2001-828607	20010406
JP 2002526167	W	WO 1999-US17222	19990730
		JP 2000-573380	19990730
AU 772479	B2	AU 1999-52417	19990730
AU 2004202345	A1	AU 2004-202345	20040526

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9952417	A Based on	WO 2000020021
EP 1117422	A1 Based on	WO 2000020021
JP 2002526167	W Based on	WO 2000020021
AU 772479	B2 Previous Publ.	AU 9952417
	Based on	WO 2000020021
AU 2004202345	A1 Div ex	AU 770725

PRIORITY APPLN. INFO: US 1998-103161P 19981006; US  
2001-828607 20010406; AU  
2004-202345 20040526

=> s nonarticular cartilage  
L7 28 NONARTICULAR CARTILAGE

=> d his

(FILE 'HOME' ENTERED AT 17:10:16 ON 01 DEC 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 17:10:42 ON 01 DEC 2004

L1 524 S CARRIER AND BIORESORBABLE  
L2 367 S L1 AND BIOCOMPATIBLE  
L3 22208 S BMP  
L4 69969 S OP  
L5 2177 S L3 AND L4  
L6 38 S L5 AND L2  
L7 28 S NONARTICULAR CARTILAGE

=> s 17 and 16  
L8 6 L7 AND L6

=> d 18 ti abs ibib tot

L8 ANSWER 1 OF 6 USPATFULL on STN

TI Repair of larynx, trachea, and other fibrocartilaginous tissues

AB Provided herein are methods and devices for inducing the formation of functional replacement **nonarticular cartilage** tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:165613 USPATFULL

TITLE: Repair of larynx, trachea, and other fibrocartilaginous tissues

INVENTOR(S): Vukicevic, Slobodan, Zagreb, Croatia

Katic, Vladimir, Zagreb, Croatia

Sampath, Kuber T., Holliston, MA, United States

PATENT ASSIGNEE(S): Creative BioMolecules, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024823	A1	20010927
APPLICATION INFO.:	US 2001-828607	A1	20010406 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US17222, filed on 30 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-103161P	19981006 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1859	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 6 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Novel methods for repairing a defect in mammalian **nonarticular cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**

AN AAY92441 protein DGENE

AB Generic Sequence 10 contains generic sequence 9 and an N-terminal extension. Generic sequence 9 is a composite amino acid sequence of the following proteins: human OP-1 to -3, human BMP-2 to -6, -9 to -11, Drosophila 60A, Xenopus Vg-1, sea urchin UNIVIN, human CDMP-1 to -3, human and mouse GDF-1, chicken DORSALIN, DPP, Drosophila Screw, mouse NODAL, mouse GDF-8 to -11, human GDF-8, -11, human BMP-15 and rat BMP3b. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, invertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92441 protein DGENE

TITLE: Novel methods for repairing a defect in mammalian

**nonarticular cartilage** tissue or ligaments  
using an osteogenic protein in a **biocompatible,**  
**bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T  
PATENT ASSIGNEE: (STYC)STRYKER CORP.  
PATENT INFO: WO 2000020021 A1 20000413 65p  
APPLICATION INFO: WO 1999-US17222 19990730  
PRIORITY INFO: US 1998-103161 19981006  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-317644 [27]  
DESCRIPTION: Generic sequence 10, derived from osteogenic protein family  
members.

L8 ANSWER 3 OF 6 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Novel methods for repairing a defect in mammalian **nonarticular**  
**cartilage** tissue or ligaments using an osteogenic protein in a  
**biocompatible, bioresorbable carrier**

AN AAY92440 protein DGENE

AB Generic Sequence 9 is a composite amino acid sequence of the following  
proteins: human OP-1 to -3, human BMP-2 to -6, -9 to  
-11, Drosophila 60A, Xenopus Vg-1, sea urchin UNIVIN, human CDMP-1 to -3,  
human and mouse GDF-1, chicken DORSALIN, DPP, Drosophila Screw, mouse  
NODAL, mouse GDF-8 to -11, human GDF-8, -11, human BMP-15 and  
rat BMP3b. The specification concerns a novel method for repairing a  
defect in a non-articular cartilage tissue or a ligament of a mammal,  
which comprises providing an osteogenic protein in a  
**biocompatible, bioresorbable carrier** to the  
defect locus to induce the formation of functional replacement cartilage.  
The methods and implants, promote chondrogenesis and are useful for  
repairing or correcting a defect in a non-articular cartilage tissue or a  
ligament of a mammal, e.g. cleft larynx, oedema of the glottis,  
ulceration of the larynx caused by syphilis, tuberculosis or malignancy,  
defects resulting from mechanical trauma to the larynx or trachea  
(including tracheotomy and laryngotomy), laryngeal cancer, and defects of  
the ear, nose, ribs, vertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92440 protein DGENE

TITLE: Novel methods for repairing a defect in mammalian  
**nonarticular cartilage** tissue or ligaments  
using an osteogenic protein in a **biocompatible,**  
**bioresorbable carrier**

INVENTOR: Vukicevic S; Katic V; Sampath K T

PATENT ASSIGNEE: (STYC)STRYKER CORP.

PATENT INFO: WO 2000020021 A1 20000413 65p

APPLICATION INFO: WO 1999-US17222 19990730

PRIORITY INFO: US 1998-103161 19981006

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-317644 [27]

DESCRIPTION: Generic sequence 9, derived from osteogenic protein family  
members.

L8 ANSWER 4 OF 6 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Novel methods for repairing a defect in mammalian **nonarticular**  
**cartilage** tissue or ligaments using an osteogenic protein in a  
**biocompatible, bioresorbable carrier**

AN AAY92439 protein DGENE

AB Generic Sequence 8 contains generic sequence 7 (AAY92438), which  
accommodates the homologies shared among osteogenic protein family  
members, including OP-1, OP-2, OP-3,  
BMP-2 to -6, 60A, DPP, Vg-1, Vgr-1 and GDF, as well as an  
N-terminal addition of 5 residues. The specification concerns a novel  
method for repairing a defect in a non-articular cartilage tissue or a  
ligament of a mammal, which comprises providing an osteogenic protein in

a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92439 protein DGENE  
TITLE: Novel methods for repairing a defect in mammalian **nonarticular cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**  
INVENTOR: Vukicevic S; Katic V; Sampath K T  
PATENT ASSIGNEE: (STYC)STRYKER CORP.  
PATENT INFO: WO 2000020021 A1 20000413 65p  
APPLICATION INFO: WO 1999-US17222 19990730  
PRIORITY INFO: US 1998-103161 19981006  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-317644 [27]  
DESCRIPTION: Generic sequence 8, derived from osteogenic protein family members.

L8 ANSWER 5 OF 6 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
TI Novel methods for repairing a defect in mammalian **nonarticular cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**  
AN AAY92438 protein DGENE  
AB Generic Sequence 7 accomodates the homologies shared among osteogenic protein family members, including OP-1, OP-2, OP-3, BMP-2 to -6, 60A, DPP, Vg-1, Vgr-1 and GDF. The specification concerns a novel method for repairing a defect in a non-articular cartilage tissue or a ligament of a mammal, which comprises providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus to induce the formation of functional replacement cartilage. The methods and implants, promote chondrogenesis and are useful for repairing or correcting a defect in a non-articular cartilage tissue or a ligament of a mammal, e.g. cleft larynx, oedema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

ACCESSION NUMBER: AAY92438 protein DGENE  
TITLE: Novel methods for repairing a defect in mammalian **nonarticular cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**  
INVENTOR: Vukicevic S; Katic V; Sampath K T  
PATENT ASSIGNEE: (STYC)STRYKER CORP.  
PATENT INFO: WO 2000020021 A1 20000413 65p  
APPLICATION INFO: WO 1999-US17222 19990730  
PRIORITY INFO: US 1998-103161 19981006  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-317644 [27]  
DESCRIPTION: Generic sequence 7, derived from osteogenic protein family members.

L8 ANSWER 6 OF 6 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
TI Novel methods for repairing a defect in mammalian **nonarticular**

**cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**.

AN 2000-317644 [27] WPIDS

CR 2000-317706 [27]

AB WO 200020021 A UPAB: 20041026

NOVELTY - Repairing a defect in a **nonarticular cartilage** tissue or a ligament of a mammal, comprising providing an osteogenic protein in a **biocompatible, bioresorbable carrier** to the defect locus, inducing the formation of functional replacement cartilage, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an implantable device for repairing a defect in a **nonarticular cartilage** tissue comprising an osteogenic protein disposed in a devitalized cartilage, a collagen **carrier**, or a carboxymethylcellulose **carrier**; and

(2) promoting chondrogenesis at a defect locus in a mammal comprising providing an osteogenic protein in a devitalized cartilage **carrier** that is configured to fit into the defect locus.

ACTIVITY - Osteogenic; chondrogenic.

MECHANISM OF ACTION - Osteopathic stimulating implant; transplantation.

USE - The methods and implants are useful for repairing or correcting a defect in a **nonarticular cartilage** tissue or a ligament of a mammal, e.g. cleft larynx, edema of the glottis, ulceration of the larynx caused by syphilis, tuberculosis or malignancy, defects resulting from mechanical trauma to the larynx or trachea (including tracheotomy and laryngotomy), laryngeal cancer, and defects of the ear, nose, ribs, intervertebral discs, and interarticular menisci.

Dwg.0/0

ACCESSION NUMBER: 2000-317644 [27] WPIDS

CROSS REFERENCE: 2000-317706 [27]

DOC. NO. CPI: C2000-096081

TITLE: Novel methods for repairing a defect in mammalian **nonarticular cartilage** tissue or ligaments using an osteogenic protein in a **biocompatible, bioresorbable carrier**.

DERWENT CLASS: A96 B04 D22

INVENTOR(S): AN, H; MASUDA, K; THONAR, E J A; KATIC, V; SAMPATH, K T; VUKICEVIC, S

PATENT ASSIGNEE(S): (ANHH-I) AN H; (RUSH-N) RUSH PRESBYTERIAN ST LUKE MEDICAL CENT; (STYC) STRYKER CORP; (CREA-N) CREATIVE BIOMOLECULES INC

COUNTRY COUNT: 23

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000020021	A1	20000413	(200027)*	EN	64
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: AU CA JP US					
AU 9952417	A	20000426	(200036)		
EP 1117422	A1	20010725	(200143)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
US 2001024823	A1	20010927	(200159)		
JP 2002526167	W	20020820	(200258)		70
AU 772479	B2	20040429	(200457)		
AU 2004202345	A1	20040624	(200468)#		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----			

WO 2000020021	A1	WO 1999-US17222	19990730
AU 9952417	A	AU 1999-52417	19990730
EP 1117422	A1	EP 1999-937624	19990730
		WO 1999-US17222	19990730
US 2001024823	A1 Provisional	US 1998-103161P	19981006
	Cont of	WO 1999-US17222	19990730
		US 2001-828607	20010406
JP 2002526167	W	WO 1999-US17222	19990730
		JP 2000-573380	19990730
AU 772479	B2	AU 1999-52417	19990730
AU 2004202345	A1	AU 2004-202345	20040526

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9952417	A Based on	WO 2000020021
EP 1117422	A1 Based on	WO 2000020021
JP 2002526167	W Based on	WO 2000020021
AU 772479	B2 Previous Publ.	AU 9952417
	Based on	WO 2000020021
AU 2004202345	A1 Div ex	AU 770725

PRIORITY APPLN. INFO: US 1998-103161P 19981006; US  
2001-828607 20010406; AU  
2004-202345 20040526